HCV NS5A inhibitors have demonstrated impressive in vitro virologic profiles in HCV replicon assays and robust HCV RNA titer reduction in the clinic making them attractive components for inclusion in an all oral fixed-dose combination (FDC) regimen for the treatment of HCV infection. Merck's effort in this area identified MK-4882 and MK-8325 as early development leads. Herein, we describe the discovery of potent macrocyclic NS5A inhibitors bearing the MK-8325 or MK-4882 core structure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2016.05.042 | DOI Listing |
Publication Analysis
Top Keywords
ns5a inhibitors
12
discovery potent
8
potent macrocyclic
8
hcv ns5a
8
hcv
5
macrocyclic hcv
4
inhibitors hcv
4
inhibitors demonstrated
4
demonstrated impressive
4
impressive vitro
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!